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Background: Ultrasound-guided foam sclerotherapy is a generally safe, cost-effective, and practical technique for the
treatment of certain venous malformations; however, not all vascular malformation lesions are amenable to the
ultrasound-guided method. Venous outflow of the sclerosing agent and extravasation are difficult to check when only
ultrasound guidance is used. This study describes a new fluoroscopy-guided technique that uses standardized sclerosing
foam for peripheral venous malformations. The short-term efficacy and safety of fluoroscopy-guided foam sclerotherapy
for peripheral venous malformations was evaluated.
Methods: A retrospective review of a prospectively collected data was performed for 23 patients (9 males, 14 females) with
limited (localized) venous malformations treated with foam sclerotherapy who were referred from January 2007 to
December 2007.Median patient age was 21 years (range, 5months-39 years). Lesion locations included extremities in 13,
faces in eight, and trunks in two. The standardized sclerosing foam was prepared using Tessari’s method to mix room air
with 5% sodium morrhuate in a 4:1 ratio. Sclerotherapy was performed by the “filling-defects” technique under
fluoroscopy. Postsclerotherapy surveillance was done at 6 months after the last session. Treatment response was assessed
clinically and by means of lesion size measurement with magnetic resonance imaging. During the treatment and the
follow-up period, adverse events and adverse drug reactions were recorded. Specific complications were classified as major
or minor.
Results: A total of 58 treatment sessions were performed (mean, 3 sessions per patient; range, 1-6 sessions). At the 6-month
follow-up, 15 patients (65.2%) showed a total disappearance of treated malformations, six (26.1%) showed a reduction in
malformation size of>50%, and two (8.7%) showed a reduction in malformation size of<50%. The overall patient-reported
outcomewas excellent in 11 (47.8%), good in 8 (34.8%), ormoderate in 4 (17.4%).Minor complications included swelling and
inflammatory reaction per session,mild pain in 17 sessions (29.3%), and skin blister at the injection site in two sessions (3.4%),
which resolved spontaneously within several days to 2 weeks. No major complications occurred.
Conclusion: Fluoroscopic guidance could have great promise in foam sclerotherapy of peripheral venous malformations,
although larger studies are necessary to determine the advantages of this technique over other sclerotherapeutic methods.
(J Vasc Surg 2009;49:961-7.)Venous malformations are difficult to treat. Various
treatment modalities, ranging from irradiation, electroco-
agulation, intravascular needles, and a long list of sclero-
sants, have been described for their management.1 Surgical
excision is difficult, and often complete removal is not
possible. Surgical treatment of more extensive lesions can
lead to loss of motor function, nerve damage, and massive
bleeding.2
Sclerotherapy is generally considered a less invasive and
more effective treatment modality.2 Traditional sclerother-
apy with liquid sclerosants has been used for many years in
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The use of liquid sclerosants has the limitations of their
dilution and progressive inactivation in a great hematic
volume and the irregular distribution of the liquid sclero-
sant on the endothelium.3
Duplex-guided foam sclerotherapy has become popu-
lar worldwide for the treatment of vascular malformations
and varicose veins in recent decades.4,5 However, it is
difficult to check for the venous outflow of the sclerosing
agent and for extravasation when only an ultrasound guid-
ance is used, and duplex ultrasound examination requires
experience.6,7 The fluoroscopy-guided technique for tradi-
tional liquid sclerotherapy has been established, but few
reports have concerned foam sclerotherapy under fluoros-
copy.
Therefore, the aim of this study was to describe a new
guidance technique of using standardized sclerosing foam
under fluoroscopy for peripheral venous malformations.
We intend to offer a way to visualize the radiolucent,
standardized sclerosing foam in real time under fluoroscopy
and to avoid local tissue damage by ensuring that the
sclerosing foam remains intravasation and does not extrav-
asate. The short-term efficacy and the safety of foam scle-
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mations were evaluated.
MATERIALS AND METHODS
Patients. The study was approved by our local ethics
committee, and informed consent was obtained from all
patients. The study design was a retrospective review of
prospectively collected data.
From January 2007 to December 2007, 23 patients (9
males, 14 females) with peripheral venous malformations
were referred to our radiology department. Patients were a
mean of 21 years old (range, 5months-39 years). Diagnosis
of venous malformations was made by clinical examination
according to guidelines for the diagnosis and therapy of the
vein and lymphatic disorders.8 This study was limited to
patients with pure venous malformations who presented
with extratruncular, limited (localized), predominantly ve-
nous defects (venous malformations) according to the
Hamburg modified classification. We excluded patients
with infiltrating (diffuse) venous malformations and com-
bined venous malformations such as Klippel-Trenaunay syn-
drome, Sturge-Weber syndrome, or Maffucci syndrome.
Lesion locations included extremities in 13 patients,
the faces in eight, and trunks in two. The patients’ initial
problems were cosmetic deformity in 18, progressive
growth of the lesion in four, and functional disability in
one. Previous treatments had failed in three patients (1
patient with sclerotherapy and two patients undergoing
surgery).
Pretreatment evaluation was individualized for each
patient. The lesion was first assessed by physical examina-
tion. Magnetic resonance imaging (MRI) studies (Signa
Infinity with EXCITE 1.5T MR scanner; General Electric
Medical Systems, Milwaukee, Wis) were done to determine
the size of lesion, the relationship to surrounding structure,
and internal blood flow of the involved vessel and to clarify
appropriate sites for percutaneous puncture. MRI include
T1-weighted spin echo imaging (repetition time [TR]/
echo time [TE], 600/20msec) and T2-weighted spin echo
imaging (TR/TE, 2500/20 msec) in multiple planes, fat-
saturated T1-weighted imaging with intravenous adminis-
tration of a gadolinium-based contrast agent, and gradient
recalled echo imaging. The fat-saturated T2-weighted im-
ages are mainly used to evaluate the extent of the abnor-
mality, whereas the gradient recalled echo images were
used to identify the lesion’s flow characteristics. Gadolinium-
enhanced images are used to determine the extent of the
malformation and distinguish venous anomalies from lym-
phatic malformations.
Sclerosing foam. The sclerosing foam was produced
by the Tessari technique using two syringes and one three-
way connector with a 4:1 air/liquid sclerosant ratio.9 This
procedure was achieved by mixing 1 mL of 5% sodium
morrhuate solution (Shanghai Donghai Pharmaceutical Co
Ltd, Donghai Pharmaceutical Factory, Shanghai, China)
and 4 mL of room air through 20 passages between two
5-mL syringes and a three-way tap (stopcock) that had 30°
rotation of the hub in order to narrow the aperture throughwhich the foam passed. The maximum doses per treatment
session were limited to 30 mL of sodium morrhuate foam,
corresponding to 6 mL of 5% sodium morrhuate solution.
Technique. The initial step was to insert percutane-
ously a 22-gauge winged needle into one of the abnormally
dilated venous sacs of the venous malformation until reflux
of venous blood was observed. Phlebography (Axiom-Artis
dFA Angiographic System, Siemens Medical Systems, Mu-
nich, Germany) under fluoroscopy or digital subtraction
angiography, or both, using a nonionic contrast medium
containing 0.5% lidocaine, was performed to verify that the
needle tip was located within the venous sacs, assess the
nature of the lesion and its draining veins, determine how
much of the lesion was accessed, and estimate the necessary
volume of sclerosing foam (Fig 1, A).
Before the sclerosing foam was injected, the blood
within lesion was partially aspirated and the limb was ele-
vated or the area was manually compressed to reduce the
volume of blood and the intralesion tension. During injec-
tion of the sclerosing foam under fluoroscopy, the scleros-
ing foam was visualized apparently as translucent filling-
defects in the lesion filled with contrast medium, while the
previously injected contrast medium was pushed to the
periphery of the lesion or towards the draining veins, or
both. The injection of the sclerosing foam was stopped
immediately once contrast medium in the lesion was com-
pletely displaced or the sclerosing foam was visualized in
the draining vein (Fig 1, B).
We routinely inject at least two to three different sites at
one sitting, provided that the volume of the 5% sodium
morrhuate solutions is6 mL. In large malformations, we
divide the lesion into arbitrary segments or quadrants. The
segments are then treated systematically from the center of
the lesion to the periphery. Random injections into a large
malformation are not advisable and may lead to multiple
pockets of untreated area. After the sclerosing foam was
injected, the needle was kept in situ for 10 minutes, ensur-
ing that the sclerosing foam was not under pressure within
the lesion and thereby reducing the possibility of extrava-
sation, which may cause skin necrosis. The needles were
then removed. We never use a tourniquet or a compression
dressing for the procedure.
Evaluation of efficacy. The primary efficacy end point
was defined as a reduction in size after the treatment was
completed. The primary end point was determined by
clinical and radiologic assessment, including MRI results in
all patients. The secondary efficacy end point included pain
reduction, cosmetic improvement, and functional improve-
ment as reported by the patient or the parents. The patients
or their parents were asked to report the end result as
excellent (clinical obliteration and asymptomatic), good
(substantial improvement in size and symptoms of 50%),
moderate improvement (significant decrease in size and
symptoms of 50%), unchanged, or worse.10
Data collection. Data on patient demographics, clin-
ical assessments, imaging studies, treatments, treatments
complications, and outcomes were obtained from the
charts, as were the results of follow-up consultations, ex-
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fined as complications that required intervention or pro-
longed hospitalization, permanent adverse sequelae, or
death. These included extensive tissue necrosis, infection,
hemorrhage, allergic reactions, deep vein thrombosis, pul-
monary embolism, or cerebral infarct. Minor complications
Fig 1. Fluoroscopy-guided foam sclerotherapy of peripheral ve-
nous malformations in the right shoulder and back region by the
filling-defects technique.A,Direct puncture venography shows an
isolated venous malformation without peripheral drainage. The
needle tip is located within the venous sacs. B, Sclerosing foam
injection under fluoroscopy. The sclerosing foam is injected into
the same area previously injected with contrast medium. The
sclerosing foam is seen as translucent filling-defects, while the
previously injected contrast is pushed to the periphery of the lesion.were defined as events that did not require interventionor prolonged hospitalization, resulted in transient self-
limiting sequelae, or required nominal therapy. The final
clinical data were updated with a telephone consultation
made to all patients who had not been reviewed during the
past 6 months before the completion of this study.
RESULTS
The procedure was technically successful in all 23 pa-
tients. Patients underwent a mean of three sessions each
(range, 1-6 sessions) for a total of 58 treatment sessions; of
these, 13 patients had only one session, and only one
patient required more than five sessions. Sessions took
place at a median interval of 5 weeks (range, 2 weeks-2
months). The average dosage of the sodium morrhuate
foam per session was 10.5 ml (2.1 mL of solution) per
patient (range, 2-30 mL; 0.5-6 mL of solution). The total
treatment dose per patient averaged 5.3 mL of solution
(range, 1-8 mL of solution).
At the follow-up 6 months after the last session, 15
patients (65.2%) showed a total disappearance of treated
malformations (Fig 2), six (26.1%) showed a reduction in
malformation size of50% (Fig 3), and 2 (8.7%) showed a
reduction in malformation size of50%. Patients reported
the overall outcome as excellent in 11 (47.8%), good in
eight (34.8%), or moderate improvement in four (17.4%).
No significant recurrences were found.
The early minor complications were self-limiting in all
cases. After treatment sessions, each patient demonstrated
an immediate swelling and inflammatory reaction that
lasted typically for 1 to 2 weeks and subsided spontane-
ously. No patients required corticosteroid to decrease in-
flammatory reaction. Mild pain in 17 sessions (29.3%)
occurred and resolved within 1 to 3 days without analgetic
drugs. Skin blister occurred at the injection site in two
sessions (3.4%) but healed uneventfully with appropriate
supportive care1 week. No cutaneous necrosis occurred,
nor did any other serious complications such as allergic
reactions, deep vein thrombosis, pulmonary embolism, or
cerebral infarct.
DISCUSSION
The first report of a large group of patients treated by
foam sclerotherapy was that of Cabrera et al.10 Their report
included 50 patients, of whom 19 had limited venous
malformations, 16 had infiltrating venous malformations,
and 15 had Klippel-Trenaunay syndrome. Sclerotherapy
was by direct injection of 0.25% to 4% polidocanol micro-
foam using ultrasound guidance. The therapy was judged
to be beneficial in 92% of the patients. Among the 46
responders, 18 showed disappearance of treated lesions, 15
had a reduction in malformation size of 50%, and 13
showed a reduction in malformation size of 50%. Of
those with severe pain, 25 of 39 patients experienced total
relief, and pain in the other 14 was significantly reduced.
No patient reported a major adverse event. There were four
cases of transient skin pigmentation and three cases of skin
necrosis.
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April 2009964 Li et alFig 2. Coronal fat-saturated T2-weighted magnetic resonance images show a venous malformation of the left
temporal region before and after treatment with fluoroscopy-guided foam sclerotherapy. A, A heterogenous mass
(arrow) is shown before treatment.B,After 30 minutes, multiple heterogenous isointense nodes (arrow) are shown.C,
Near complete resolution of the left temporal venous malformation (arrow) is revealed att the 6-month follow-up.
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foam sclerotherapy in a patient with venous malformations
of the face. Subsequently, similar results were reported by
Bergan et al,12-14 Nitecki et al,15 Tan et al,16 and Yamaki et
al.17 The imaging tool to guide foam sclerotherapy was at
all times duplex ultrasound in these reports, both for vari-
Fig 3. Sagittal fat-saturated T2-weighted magnetic resonance
images show a venous malformation of the right facial region
before and after treatment with fluoroscopy-guided foam sclero-
therapy. A, Image shows a heterogenous mass (arrow) before
treatment. B, An image 6 six months later reveals substantial
improvement in size of 50% of the left facial venous malforma-
tion (arrow).cose veins and vascular malformations.3-5,2-17The ultrasound-guided technique is not perfect, how-
ever, and correlative complications have been reported.
Complications due to difficulties in visualization of the
needle tip with ultrasound imaging include accidental ex-
travascular, intra-arterial, or deep venous injections.18 Sys-
temic complications due to difficulties in checking for the
venous outflow of the sclerosing foam using ultrasound
guidance include chest tightness, dry cough, headache,
cutaneous necrosis, superficial thrombophlebitis, periph-
eral nerve damage, transient visual disturbances, ischemic
stroke (air embolus), and deep venous thrombosis.19-22
The fluoroscopy-guided technique for traditional liq-
uid sclerotherapy has been established.23 Direct puncture
phlebography has an important role to visualize the intrale-
sional flow characteristics, including the venous drainage
pathways before percutaneous sclerotherapy.24 Moreover,
fluoroscopic guidance was useful to reduce the risk of the
sclerosant reflux into the superficial veins or the central
venous system during percutaneous sclerotherapy of ve-
nous malformations.25,26 It is strange that the fluoroscopy-
guided technique for foam sclerotherapy has not been
reported heretofore. This is because the sclerosing foam is
radiolucent and therefore not easily visualized.
In traditional liquid sclerotherapy, the liquid sclerosant
can be visualized under fluoroscopy by mixing it with
moderate doses of contrast media. Lord et al27 in 2003
suggested that the foam sclerosant was opacified under
fluoroscopy by addition of ethiodized oil. The liquid scle-
rosant mixed with a little contrast media only produces
pastel shades in the fluoroscopic images; moreover, we do
not know whether peculiar properties of the sclerosing
foam mentioned by Frullini et al4 would be changed by
mixing contrast media or lipiodol, and whether the chem-
ical reaction would be set off bymixing the liquid sclerosant
with contrast media. At least there is currently no clear
evidence to support it. We therefore propose a method for
tracing the standardized sclerosing foam under fluoros-
copy.
The most popular foam sclerosants include sodium
tetradecyl sulfate and polidocanol.3-5,12-17 These are not
obtainable in China, however; only sodium morrhuate is
available to make the foam sclerosant. Sodiummorrhuate is
one of the detergent sclerosants. It was introduced in the
1920s and was applied first to the treatment of varicose
veins in 1930,28 and is still available today. The early users
have found that sodium morrhuate could form bubbles
when agitated. Therefore, we use 5% sodium morrhuate
solution to produce the standardized foam sclerosant (the
air/liquid ratio is 4:1) by the Tessari technique.
Our study offers a simple and elegant way to visualize in
real time the standardized sclerosing foam injected into
venous sacs of venous malformations under fluoroscopy.
After direct puncture, angiography is performed to confirm
needle tip localization in the lesion. The injected sclerosing
foam replaces the previously injected contrast medium and
appears as radiolucent filling-defects. In contrast with the
previously injected contrast medium, the venous outflow of
the sclerosing foam is visualized clearly. Thus, it is quite
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into the adjacent tissue or the draining veins occurs, the
procedure can be stopped immediately. We call this
method “the filling-defects technique under fluoroscopy.”
Systemic complications with foam sclerotherapy could re-
sult from small amounts of foam or air entering into the
deep venous system during the treatment. This new tech-
nique showed the potential to reduce the risk involved from
those systemic complications by better control of the foam
under fluoroscopic guidance.
Our results seem to be superior to those published by
other authors.10,16 In our preliminary data, after a mean of
three treatment sessions per patient and at the 6-month
follow-up, 15 of our 23 patients (65.2%) showed a total
disappearance of treated malformations, malformation size
was reduced50% in six (26.1%), and50% in two (8.7%).
The patient-reported overall outcome was excellent in 11
(47.8%), good in eight (34.8%), or moderate improvement
in four (17.4%). No significant recurrences were found at
the 6-month follow-up after the last session. In all patients,
the goal of reduction of lesion size was achieved without
major complications.
Cabrera et al10 reported 50 patients with congenital
venous malformations treated with sclerotherapy using po-
lidocanol microfoam under duplex ultrasound guidance.
Of 19 patients with limited venous malformations, 7 (37%)
showed a total disappearance of treated malformations, the
reduction in malformation size was 50% in (37%) and
50% in 4 (28%), and 1 (5%) was unchanged. Tan et al16
reported the efficacy, safety, and long-term outcomes of
percutaneous sodium tetradecyl sulfate foam sclerotherapy
for 78 patients with peripheral venous vascular malforma-
tions. Limited venous malformations were present in 22
patients, of whom 8 (36.4%) became asymptomatic, 5
(21.7%) rated the response to therapy as good, 6 (27.3%)
improved, 2 (9.1%) were unchanged, and 1 (4.5%) wors-
ened. The size of themalformation onMRI decreased in 18
patients and was unchanged in four. Possible explanation
for the discrepancy is that 5% sodium morrhuate foam may
be more effective than 0.25% to 4% polidocanol micro-
foam10 or 2% sodium tetradecyl sulfate foam.16 These small
case series are not enough to be convincing, however, so
large studies need to further confirm our results.
No skin necrosis was encountered in our preliminary
study. In recent reports on ultrasound-guided foam sclero-
therapy for the treatment of venous malformations, skin
necrosis was seen in 3 of 50 patients reported by Cabrera et
al,10 in l of 10 patients reported by Pascarella et al,13 1 of 14
reported by Bergan et al,14 and 1 of 44 reported by Yamaki
et al.17 A randomized controlled trial should be required to
confirm this issue.
This study has several limitations. First, the study group
was relatively small and there was no control group. Sec-
ond, the study was limited to patients with extratruncular
limited (localized) venous malformations according to the
Hamburg modified classification. Third, further long-term
assessment, especially for recurrence and sequelae, is abso-
lutely warranted. Fourth, the efficacy, safety, and clinicaloutcomes between two guided techniques (ultrasound or
fluoroscopy) of percutaneous foam sclerotherapy for pe-
ripheral venous malformations were not compared. Finally,
the efficacy between sodium morrhuate foam and polido-
canol foam (or sodium tetradecyl sulfate) for peripheral
venous malformations should be compared.
CONCLUSIONS
Our initial results show that fluoroscopy-guided foam
sclerotherapy of peripheral venous malformations using
sodium morrhuate is an effective method without serious
complications. Further studies are needed to evaluate the
clinical value of fluoroscopy-guided foam sclerotherapy by
the large case-series analysis and randomized controlled
trials.
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